1. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice
- Author
-
Guorgui, Jacob, Wang, Ruixue, Mattheolabakis, George, and Mackenzie, Gerardo G
- Subjects
Biochemistry & Molecular Biology ,Curcumin ,Lymphoma ,Drug Compounding ,SLN ,TPGS ,Cell Line ,Mice ,Rare Diseases ,Complementary and Integrative Health ,Animals ,Tissue Distribution ,Cancer ,Tumor ,Hodgkin's lymphoma ,Tumor Necrosis Factor-alpha ,Interleukin-6 ,Hematology ,Hodgkin Disease ,Lipids ,Xenograft Model Antitumor Assays ,5.1 Pharmaceuticals ,Nanoparticles ,Female ,Biochemistry and Cell Biology ,Development of treatments and therapeutic interventions - Abstract
Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (TPGS-curc) could enhance its efficacy in mice. Curcumin formulated in SLN and in TPGS resulted in higher curcumin plasma levels in mice. Compared to vehicle-treated controls, SLN-curc and TPGS-curc reduced HL xenograft growth by 50.5% (p
- Published
- 2018